TIDMRENX
Renalytix PLC
10 November 2021
Renalytix plc
("Renalytix" or the "Company")
Renalytix Convenes Expert Panel at VA Healthcare Summit
Leading clinicians discuss enabling long-term kidney health in
Veterans with type 2 diabetes and early-stage chronic kidney
disease
NEW YORK and SALT LAKE CITY, November 10, 2021 - In recognition
of National Diabetes Month and concurrent with the launch of
KidneyIntelX in the Veterans Health Administration health system,
Renalytix (NASDAQ: RNLX) (LSE: RENX) convened a multidisciplinary
panel to discuss advances in kidney health through early-stage
prognosis and intervention of chronic kidney disease (CKD) in
patients with type 2 diabetes. Clinical experts shared patient case
studies drawing from their experience adding KidneyIntelX into
clinical care. The KidneyIntelX enabled care pathway being
implemented in the Mount Sinai Health System is a model that can be
used in implementing the new Veterans Health Administration CKD
Directive and joint VA and Department of Defense guideline, driving
care earlier to prevent progression and kidney failure. The panel
event took place at The Institute for Defense and Government
Advancement (IDGA) VA Healthcare Summit on Wednesday, October 27,
2021.
The panel, "Breakthrough Diagnostic Approach for Type 2 Diabetes
and Early-Stage Chronic Kidney Disease (CKD): Today's Precise
Answer, Tomorrow's Kidney Health," included renowned thought
leaders who highlighted the importance of early detection and
intervention to promote long-term kidney health and improve
clinical outcomes in their type 2 diabetes patients.
Commenting on the Summit discussion, panelists said:
Michael J. Donovan, PhD, MD, Chief Medical Officer at Renalytix:
"This roundtable discussion provided a unique opportunity for
clinical experts to highlight the impact of KidneyIntelX risk
assessment on patient-specific management decisions. Their remarks
highlighted how KidneyIntelX testing can help address the
challenges they face when relying on current clinical tools. The
panel also reviewed the practice-changing evidence from recent
therapeutic trials. The discussion underscored the importance of a
systems approach to managing care for chronic kidney disease
patients given the intimate association of cardiovascular and
kidney function."
David Lam, MD, Assistant Professor of Medicine (Endocrinology,
Diabetes and Bone Disease) at the Icahn School of Medicine at Mount
Sinai and Medical Director at the Mount Sinai Clinical Diabetes
Institute, NYC, NY: "As an endocrinologist, I see patients living
with diabetes day in and day out. Diabetes care is a team effort. I
co-manage diabetic patients with other trained professionals, all
working towards the care of patients to help them thrive.
KidneyIntelX has helped me to identify patients with early-stage
diabetic kidney disease earlier and has enabled me to deploy the
right care path, direct care resources and provide treatment
guidance based on my patients' risk level at the right time."
Joseph Vassalotti, MD, FASN, Clinical Professor of Medicine
(Nephrology) at Icahn Mount Sinai and Chief Medical Officer of the
National Kidney Foundation, NYC, NY : "13.1 % of the US population
has diabetes, most with type 2 diabetes, but about 40% also have
low kidney function and/or increased albumin, a type of protein, in
the urine. Early risk stratification for these patients with kidney
disease informs their care management. KidneyIntelX combines
biomarkers and the data from the patients' health record, to
produce a risk score that is easy to understand. For patients,
reviewing the results of that risk score helps motivate them to
take additional action toward their kidney health that is
proportional to the risk. As a nephrologist it helps me think about
the types of lifestyle modification, patient engagement, medication
management and interdisciplinary care that is optimal for my
patients."
Katherine Tuttle, MD, FASN, FACP, FNKF, Professor of Medicine in
Nephrology at the University of Washington, the Executive Director
for Research at Providence Health Care, and a Co-Principal
Investigator at the Institute for Translational Health Sciences : "
KidneyIntelX leads into more effective therapeutic management which
should lead to improved outcomes in a value-based system. For
example, heart failure and chronic kidney disease occur
concomitantly. If we reduce heart failure hospitalization by
identifying and managing higher risk patients more effectively,
that would be a huge savings to the health care system. If we also
prevent cases of kidney failure, and the costs associated with
treating patients with kidney failure, we will realize enormous
cost savings. The triangulation between diabetes, heart failure and
chronic kidney disease accounts for one third of the Medicare
budget and this cost is extensive in the veteran population as
well."
As the largest integrated health care network in the United
States, the U.S. Department of Veterans Affairs is tasked with
providing care to America's Veterans. One in four veterans have
diabetes and many have comorbid conditions including kidney
disease. Renalytix is committed to promoting kidney health in
veterans by aligning care models that proactively protect kidneys
from avertable harm.
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker Tel: 020 7710 7600
)
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584
391 303
CapComm Partners Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and one out of two people with very low kidney
function who are not on dialysis do not know they have CKD.(1)
Kidney disease is referred to as a "silent killer" because it often
has no symptoms and can go undetected until a very advanced stage.
Each year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables
early-stage diabetic kidney diseases (DKD) progression risk
assessment by combining diverse data inputs, including validated
blood-based biomarkers, inherited genetics, and personalized
patient data from electronic health record, or EHR, systems, and
employs a proprietary algorithm to generate a unique patient risk
score. This patient risk score enables prediction of progressive
kidney function decline in CKD, allowing physicians and healthcare
systems to optimize the allocation of treatments and clinical
resources to patients at highest risk.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and
leader in the new field of bioprognosis(TM) for kidney health. The
company has engineered a new solution that successfully enables
early-stage chronic kidney disease, progression risk assessment.
The Company's lead product, KidneyIntelX, has been granted
Breakthrough Designation by the U.S. Food and Drug Administration
and is designed to help make significant improvements in kidney
disease prognosis, transplant management, clinical care, patient
stratification for drug clinical trials, and drug target discovery
(visit www.kidneyintelx.com ). For more information, visit
www.renalytix.com .
KidneyIntelX is based on technology developed by Mount Sinai
faculty and licensed to Renalytix, and is currently utilized in
sponsored research by Renalytix at Mount Sinai. Mount Sinai and
Mount Sinai faculty, including Dr. Steve Coca and Dr. Girish
Nadkarni, have a financial interest in Renalytix. Mount Sinai has
representation on the Renalytix Board of Directors.
Sources
1
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Examples of these forward-looking statements
include statements concerning: the potential benefits, including
economic savings, of KidneyIntelX, the potential for KidneyIntelX
to receive regulatory approval from the FDA, the commercial
prospects of KidneyIntelX, if approved, including whether
KidneyIntelX will be successfully adopted by physicians and
distributed and marketed, our expectations regarding reimbursement
decisions and the ability of KidneyIntelX to curtail costs of
chronic and end-stage kidney disease, optimize care delivery and
improve patient outcomes. Words such as "anticipates," "believes,"
"estimates," "expects," "intends," "plans," "seeks," and similar
expressions are intended to identify forward-looking statements. We
may not actually achieve the plans and objectives disclosed in the
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Any forward-looking statements
are based on management's current views and assumptions and involve
risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
among others: that
KidneyIntelX is based on novel artificial intelligence
technologies that are rapidly evolving and potential acceptance,
utility and clinical practice remains uncertain; we have only
recently commercially launched KidneyIntelX; and risks relating to
the impact on our business of the COVID-19 pandemic or similar
public health crises. These and other risks are described more
fully in our filings with the Securities and Exchange Commission
(SEC), including the "Risk Factors" section of our annual report on
Form 20-F filed with the SEC on October 21, 2021, and other filings
we make with the SEC from time to time. All information in this
press release is as of the date of the release, and we undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise, except as required by law.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKCBQKBDBCDK
(END) Dow Jones Newswires
November 10, 2021 02:00 ET (07:00 GMT)
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
